64 related articles for article (PubMed ID: 11716533)
1. Antitumor activity of type III interferon alone or in combination with type I interferon against human non-small cell lung cancer.
Fujie H; Tanaka T; Tagawa M; Kaijun N; Watanabe M; Suzuki T; Nakayama K; Numasaki M
Cancer Sci; 2011 Nov; 102(11):1977-90. PubMed ID: 21883692
[TBL] [Abstract][Full Text] [Related]
2. Effects of tumor necrosis factor alpha, interferon alpha and interferon gamma on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation.
Kikuchi A; Holán V; Minowada J
Cancer Immunol Immunother; 1992; 35(4):257-63. PubMed ID: 1511460
[TBL] [Abstract][Full Text] [Related]
3. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
Taura M; Fukuda R; Suico MA; Eguma A; Koga T; Shuto T; Sato T; Morino-Koga S; Kai H
Cancer Sci; 2010 Jul; 101(7):1610-7. PubMed ID: 20367642
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of tamoxifen and tumor necrosis factor alpha on human glioblastoma cells.
Iwasaki K; Toms SA; Barnett GH; Estes ML; Gupta MK; Barna BP
Cancer Immunol Immunother; 1995 Apr; 40(4):228-34. PubMed ID: 7750120
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.
Paterson J; Uriel C; Egron MJ; Herscovici J; Antonakis K; Alaoui-Jamali MA
Antimicrob Agents Chemother; 1998 Apr; 42(4):779-84. PubMed ID: 9559782
[TBL] [Abstract][Full Text] [Related]
6.
Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819
[No Abstract] [Full Text] [Related]
7. Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro.
Wen Z; Jia Q; Kang X; Lou Y; Zou L; Yang J; Gao J; Han L; Li X
Anticancer Drugs; 2017 Jan; 28(1):31-39. PubMed ID: 27759573
[TBL] [Abstract][Full Text] [Related]
8. p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism.
Acosta J; Li Q; Freeburg NF; Murali N; Indeglia A; Grothusen GP; Cicchini M; Mai H; Gladstein AC; Adler KM; Doerig KR; Li J; Ruiz-Torres M; Manning KL; Stanger BZ; Busino L; Murphy M; Wan L; Feldser DM
Nat Commun; 2023 Jul; 14(1):4403. PubMed ID: 37479684
[TBL] [Abstract][Full Text] [Related]
9. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.
Wilcken R; Liu X; Zimmermann MO; Rutherford TJ; Fersht AR; Joerger AC; Boeckler FM
J Am Chem Soc; 2012 Apr; 134(15):6810-8. PubMed ID: 22439615
[TBL] [Abstract][Full Text] [Related]
10. Mutation of p53 increases the competitive ability of pluripotent stem cells.
Perez Montero S; Paul PK; di Gregorio A; Bowling S; Shepherd S; Fernandes NJ; Lima A; Pérez-Carrasco R; Rodriguez TA
Development; 2024 Jan; 151(2):. PubMed ID: 38131530
[TBL] [Abstract][Full Text] [Related]
11. Expression of HYOU1 via Reciprocal Crosstalk between NSCLC Cells and HUVECs Control Cancer Progression and Chemoresistance in Tumor Spheroids.
Lee M; Song Y; Choi I; Lee SY; Kim S; Kim SH; Kim J; Seo HR
Mol Cells; 2021 Jan; 44(1):50-62. PubMed ID: 33455947
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of protein interactome networks prioritizes candidate genes with cancer signatures.
Li Y; Sahni N; Yi S
Oncotarget; 2016 Nov; 7(48):78841-78849. PubMed ID: 27791983
[TBL] [Abstract][Full Text] [Related]
13. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
Liu D; Liu X; Xing M
Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
[TBL] [Abstract][Full Text] [Related]
14. Interferons induce the expression of IFITM1 and IFITM3 and suppress the proliferation of rat neonatal cardiomyocytes.
Lau SL; Yuen ML; Kou CY; Au KW; Zhou J; Tsui SK
J Cell Biochem; 2012 Mar; 113(3):841-7. PubMed ID: 22021094
[TBL] [Abstract][Full Text] [Related]
15. Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.
Del Monte P; Laurino C; Arvigo M; Palermo C; Minuto F; Barreca A
J Endocrinol Invest; 2005 May; 28(5):432-9. PubMed ID: 16075927
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate lung cancer susceptibility genes in mouse using oligonucleotide arrays.
Lemon WJ; Bernert H; Sun H; Wang Y; You M
J Med Genet; 2002 Sep; 39(9):644-55. PubMed ID: 12205107
[TBL] [Abstract][Full Text] [Related]
17. Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line.
Yasuoka Y; Naomoto Y; Yamatsuji T; Takaoka M; Kimura M; Uetsuka H; Matsubara N; Fujiwara T; Gunduz M; Tanaka N; Haisa M
Exp Cell Res; 2001 Dec; 271(2):214-22. PubMed ID: 11716533
[TBL] [Abstract][Full Text] [Related]
18. IFN-alpha enhances TNF-alpha-induced apoptosis through down-regulation of c-Myc protein expression in HL-60 cells.
Nakashima A; Kumakura S; Mishima S; Ishikura H; Kobayashi S
J Exp Clin Cancer Res; 2005 Sep; 24(3):447-56. PubMed ID: 16270532
[TBL] [Abstract][Full Text] [Related]
19. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
